Hemoperfusion removal of digoxin from dogs

Area of Science:

• Pharmacology
• Toxicology
• Medical Devices

Background:

• Digoxin is a critical medication for heart conditions.
• Effective methods for digoxin removal are essential for managing toxicity.
• XAD-4 hemoperfusion is a potential therapeutic intervention.

Purpose of the Study:

• To evaluate the efficacy of XAD-4 hemoperfusion for digoxin removal in a canine model.
• To analyze the pharmacokinetic changes associated with hemoperfusion.
• To understand digoxin distribution in canine blood and plasma.

Main Methods:

• Intravenous administration of digoxin to four dogs.
• Hemoperfusion using XAD-4 columns at a flow rate of 105 ml/min for 4-5 hours.
• Pharmacokinetic analysis using a three-compartment model.
• Measurement of digoxin levels in blood and plasma using 3H-digoxin.

Main Results:

• Hemoperfusion decreased the apparent half-life of digoxin from 16.0 to 7.1 hours.
• Digoxin perfusion clearance was 46 ml/min, exceeding plasma flow.
• Canine whole blood contained 2.5 times more digoxin than plasma.
• Serum digoxin levels increased post-perfusion due to refilling from peripheral compartments.

Conclusions:

• XAD-4 hemoperfusion effectively doubles the rate of digoxin removal in dogs.
• Hemoperfusion clearance is significantly influenced by digoxin's higher concentration in whole blood.
• A multicompartmental model accurately explains post-hemoperfusion digoxin level dynamics.